PDF(Pubmed)
Abstract：
UNASSIGNED: The purpose of this study is to address the high mortality and poor prognosis associated with Acute Respiratory Distress Syndrome (ARDS), conditions characterized by acute and progressive respiratory failure. The primary goal was to prolong drug circulation time, increase drug accumulation in the lungs, and minimize drug-related side effects.
UNASSIGNED: Simvastatin (SIM) was used as the model drug in this study. Employing a red blood cell surface-loaded nanoparticle drug delivery technique, pH-responsive cationic nanoparticles loaded with SIM were non-covalently adsorbed onto the surface of red blood cells (RBC), creating a novel drug delivery system (RBC@SIM-PEI-PPNPs).
UNASSIGNED: The RBC@SIM-PEI-PPNPs delivery system effectively extended the drug\'s circulation time, providing an extended therapeutic window. Additionally, this method substantially improved the targeted accumulation of SIM in lung tissues, thereby enhancing the drug\'s efficacy in treating ARDS and impeding its progression to ARDS. Crucially, the system showed a reduced risk of adverse drug reactions.
UNASSIGNED: RBC@SIM-PEI-PPNPs demonstrates promise in ARDS and ARDS treatment. This innovative approach successfully overcomes the limitations associated with SIM\'s poor solubility and low bioavailability, resulting in improved therapeutic outcomes and fewer drug-related side effects. This research holds significant clinical implications and highlights its potential for broader application in drug delivery and lung disease treatment.
UNASSIGNED: Simvastatin (SIM) was used as the model drug in this study. Employing a red blood cell surface-loaded nanoparticle drug delivery technique, pH-responsive cationic nanoparticles loaded with SIM were non-covalently adsorbed onto the surface of red blood cells (RBC), creating a novel drug delivery system (RBC@SIM-PEI-PPNPs).
UNASSIGNED: The RBC@SIM-PEI-PPNPs delivery system effectively extended the drug\'s circulation time, providing an extended therapeutic window. Additionally, this method substantially improved the targeted accumulation of SIM in lung tissues, thereby enhancing the drug\'s efficacy in treating ARDS and impeding its progression to ARDS. Crucially, the system showed a reduced risk of adverse drug reactions.
UNASSIGNED: RBC@SIM-PEI-PPNPs demonstrates promise in ARDS and ARDS treatment. This innovative approach successfully overcomes the limitations associated with SIM\'s poor solubility and low bioavailability, resulting in improved therapeutic outcomes and fewer drug-related side effects. This research holds significant clinical implications and highlights its potential for broader application in drug delivery and lung disease treatment.
摘要：
■这项研究的目的是解决与急性呼吸窘迫综合征（ARDS）相关的高死亡率和不良预后，以急性和进行性呼吸衰竭为特征的病症。主要目标是延长药物循环时间，增加药物在肺部的积累，尽量减少药物相关的副作用。
■在本研究中使用辛伐他汀（SIM）作为模型药物。采用红细胞表面负载纳米颗粒药物递送技术，负载有SIM的pH响应性阳离子纳米粒子非共价吸附到红细胞（RBC）的表面，创建一个新的药物递送系统（RBC@SIM-PEI-PPNP）。
■RBC@SIM-PEI-PPNPs输送系统有效地延长了药物的循环时间，提供一个扩展的治疗窗口。此外,这种方法大大改善了SIM在肺组织中的靶向积累，从而增强药物治疗ARDS的疗效并阻止其进展为ARDS。至关重要的是，该系统显示药物不良反应的风险降低。
■RBC@SIM-PEI-PPNPs在ARDS和ARDS治疗中显示出希望。这种创新的方法成功地克服了与SIM的低溶解度和低生物利用度相关的限制，导致改善的治疗结果和更少的药物相关的副作用。这项研究具有重要的临床意义，并强调了其在药物递送和肺部疾病治疗中更广泛的应用潜力。
■在本研究中使用辛伐他汀（SIM）作为模型药物。采用红细胞表面负载纳米颗粒药物递送技术，负载有SIM的pH响应性阳离子纳米粒子非共价吸附到红细胞（RBC）的表面，创建一个新的药物递送系统（RBC@SIM-PEI-PPNP）。
■RBC@SIM-PEI-PPNPs输送系统有效地延长了药物的循环时间，提供一个扩展的治疗窗口。此外,这种方法大大改善了SIM在肺组织中的靶向积累，从而增强药物治疗ARDS的疗效并阻止其进展为ARDS。至关重要的是，该系统显示药物不良反应的风险降低。
■RBC@SIM-PEI-PPNPs在ARDS和ARDS治疗中显示出希望。这种创新的方法成功地克服了与SIM的低溶解度和低生物利用度相关的限制，导致改善的治疗结果和更少的药物相关的副作用。这项研究具有重要的临床意义，并强调了其在药物递送和肺部疾病治疗中更广泛的应用潜力。
